SAN DIEGO — In early cuts of data, the next iteration of KRAS drugs for lung cancer appears to bear more promise than the first.

UCB plans to pay $650 million to Neurona Therapeutics in a bid to broaden its clinical-stage epilepsy portfolio. The deal comes with as much as

A year after pulling its first try at an IPO, Odyssey Therapeutics is giving it another go. On Friday night, the Boston-based biotech submitted its

Donald Trump has signed an executive order directing the FDA to reduce regulatory hurdles that stand in the way of bringing psychedelics to patients.

A trio of scientists behind the first gene therapy approved in the United States have been awarded a Breakthrough Prize in Life Sciences. It’s arguably